| Literature DB >> 25205080 |
María Luisa Gutiérrez García1, Sonia Alonso Lopez2, María Dolores Martín Rios3, Patricia Sanmartin Fenollera4, Sandra Agudo Fernandez2, Conrado Manuel Fernández Rodriguez2.
Abstract
Hepatitis B virus (HBV) reactivation after chemotherapy regimens is a well-known complication. The incidence and risk factors for HBV reactivation remain to be elucidated. We aimed to determine the incidence and risk factors for HBV reactivation in patients receiving rituximab, and the potential role of the cumulative rituximab dose in HBV reactivation. We retrospectively reviewed 320 patients receiving rituximab in our hospital. Of these, 42 (13.12%) had serological markers of hepatitis B. During follow-up, 21% (9/42) had HBV reactivation. Risk factors for reactivation were HBsAg positivity (p < 0.05), isolated anti-HBc positivity (p < 0.05), marginal zone lymphoma, and Mantle cell lymphoma (p < 0.05). The median rituximab dose tended to be higher in patients with reactivation (p = 0.06).Entities:
Keywords: Hematological disease; Hepatitis B virus reactivation; Neoplasias hematológicas; Reactivación del virus de la hepatitis B; Rituximab
Mesh：
Substances：
Year: 2014 PMID： 25205080 DOI： 10.1016/j.gastrohep.2014.05.008
Source DB: PubMed Journal: Gastroenterol Hepatol ISSN： 0210-5705 Impact factor: 2.102